Tandem Diabetes Care
TNDM
80 hedge funds and large institutions have $27.8M invested in Tandem Diabetes Care in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 12 closing their positions.
983% more capital inflows, than outflows
Capital inflows: $28.6M | Capital outflows: $2.64M
100% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 14
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
7.95% more ownership
Funds ownership: 38.96% → 46.9% (+7.9%)
7% more funds holding
Funds holding: 75 → 80 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Frontier Capital Management
Boston,
Massachusetts
|
+$8.33M |
| 2 |
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.13M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.5M |
| 4 |
BlackRock
New York
|
+$2.23M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
-$591K |
| 2 |
Bank of New York Mellon
New York
|
-$316K |
| 3 |
Renaissance Technologies
New York
|
-$302K |
| 4 |
FDx Advisors
Chicago,
Illinois
|
-$210K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$147K |
TNDM Hedge Fund Activity: Q1 2017 in Review
80 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q1 2017, worth a combined $27.8M — up 5.9% from $26.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TNDM positions and 12 closed out — a net gain of 9 holders — while 28 added to existing stakes and 14 trimmed.
The largest buyer was Frontier Capital Management, adding an estimated $8.33M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $591K sold.
- 80 institutional investors held Tandem Diabetes Care (TNDM) as of Q1 2017, up from 75 in Q4 2016.
- Funds reported $27.8M of Tandem Diabetes Care stock for Q1 2017, up 5.9% quarter-over-quarter.
- 21 funds opened new Tandem Diabetes Care positions in Q1 2017 and 12 closed out, a net change of +9 holders.
- The largest Tandem Diabetes Care buyer in Q1 2017 was Frontier Capital Management, an estimated $8.33M added.
- The largest Tandem Diabetes Care seller in Q1 2017 was Eventide Asset Management, an estimated $591K sold.
Based on aggregated 13F filings for Q1 2017.